Reference number(s)
7310-A

Specialty Guideline Management
Redemplo

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Redemplo	plozasiran

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-approved Indications[1]

Redemplo is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).

Documentation

Submission of the following information is necessary to initiate the prior authorization review:

Initial requests:

- Genetic test(s) confirming diagnosis of FCS.
- Chart notes or medical record documentation indicating North American familial syndrome (NAFCS) score or Moulin score (if applicable).
- Laboratory tests or medical record documentation of fasting triglycerides (TG) level.

© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Continuation requests:

- Chart notes or medical record documentation supporting positive clinical response.

Prescriber Specialties

This medication must be prescribed by or in consultation with a cardiologist, endocrinologist, lipid specialist, geneticist, or a prescriber specialized in the treatment of FCS.

Coverage Criteria

Familial chylomicronemia syndrome (FCS)[1-9]

Authorization of 12 months may be granted for treatment of familial chylomicronemia syndrome (FCS) (type 1 hyperlipoproteinemia) in adult members when all of the following criteria are met:

- Member meets either of the following:
    - Member has a confirmed FCS diagnosis by genetic testing (i.e., biallelic pathogenic variants in FCS-causing genes [e.g., LPL, GPIHBP1, APOA5, APO2, LMF1, GPD1, CREB3L3]).
    - Genetic testing was inconclusive, and the member has confirmed FCS diagnosis by either of the following:
        - North American familial chylomicronemia syndrome (NAFCS) score greater than or equal to 45.
        - Moulin score greater than or equal to 10.
- Member has a fasting triglycerides (TG) level of more than or equal to 880 mg/dL.
- Member is currently receiving a very-low fat diet (e.g., less than 20 to 30 g of total fat per day, 10% to 15% of calories of fat).
- Member will not use the requested medication concomitantly with Tryngolza.

Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in adult members requesting reauthorization for FCS when both of the following criteria are met:

- Member has demonstrated a positive clinical response with the requested medication (e.g., reduction in TG level from baseline, reduction in episodes of acute pancreatitis).
- Member is currently receiving a very-low fat diet (e.g., less than 20 to 30 g of total fat per day, 10% to 15% of calories per day of fat).

© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

- Member will not use the requested medication concomitantly with Tryngolza.

References

1. Redemplo [package insert]. Pasadena, CA: Arrowhead Pharmaceuticals, Inc.; November 2025.
2. Watts GF, Rosenson RS, Hegele RA et al. Plozasiran for managing persistent chylomicronemia and pancreatitis risk. N Engl J Med.2025; 392 (2): 127-137.
3. Falko JM. Familial chylomicronemia syndrome: a clinical guide for endocrinologists. *Endocr Pract*. 2018;24(8):756-763.
4. Hegele RA, Boren J, Ginsberg HN, et al. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. *Lancet Diabetes Endocrinol*. 2020;8(1):50-67.
5. Spagnuolo CM, Hegele RA. Etiology and emerging treatments for familial chylomicronemia syndrome. Expert Rev Endocrinol Metab. 2024;19(4):299-306.
6. Javed F, Hegele RA, Garg A et al. Familial chylomicronemia syndrome: An expert clinical review from the National Lipid Association. *J Clin Lipidol*.2025; 19:382-403.
7. Hegele RA, Ahmad Z, Ashraf A, et al. Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America. *J Clin Lipidol*. 2025;19(1):83-94.
8. Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an “FCS score”. *Atherosclerosis*. 2018;275:265-272.
9. Brown AS, Moulin P, Dibble A et al. Brief communication: Strong concordance of the North American Familial Chylomicronemia Syndrome Score with a positive genetic diagnosis in patients from the Balance study. *J Clin Lipidol*. 2025; 11(16): 1-6.

© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.